ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
38 announcements with these filters
Dishman Carbogen Amcis Ltd fixed the record date for interest and partial redemption of its NCDs (ISIN: INE385W07059). The redemption totals ₹4.17 Crore.
Dishman Carbogen Amcis Ltd has made the sixth quarterly interest payment of ₹1.26 Crore on its non-convertible debentures as per Regulation 57(1).
Dishman Carbogen Amcis' subsidiary, Carbogen Amcis AG, successfully completed a US FDA inspection at its Vionnaz, Switzerland site without any observations.
Dishman Carbogen Amcis Ltd paid the first quarterly interest of ₹0.45 Crore on its Non-Convertible Debentures (ISIN: INE385W07067), complying with SEBI regulations.
Dishman Carbogen Amcis Ltd has fixed September 11, 2026, as the record date for the sixth quarterly interest payment on its non-convertible debentures.
Dishman Carbogen Amcis Ltd submitted the Notice of its 19th Annual General Meeting and the Annual Report for FY 2025-26. The AGM is scheduled for September 30, 2026.
Dishman Carbogen Amcis Limited has scheduled its 19th Annual General Meeting for September 30, 2026, to be conducted via video conferencing.
Dishman Carbogen Amcis Limited announced the cessation of Mr. Deepak Ram Chandra Mittal from his position as Vice President (Operation), effective from August 27, 2026.
Dishman Carbogen Amcis Limited announced the allotment of debt securities on August 17, 2026. This follows board approval for fund raising via non-convertible securities.
Q1FY27 revenue fell 4.3% YoY to ₹6,776mn, with EBITDA margins dropping sharply to 8.9% due to CDMO project deferments and fixed costs.
Dishman Carbogen Amcis Ltd submitted a statement confirming the utilization of proceeds from non-convertible debt securities issued on June 9, 2026, with no deviations.
Dishman Carbogen Amcis Ltd reported revenue from operations of ₹677.6 Cr (-4.3% YoY) and a net loss of ₹57.9 Cr for Q1 FY27.
Dishman Carbogen Amcis approved the issuance of 7,500 secured Non-Convertible Debentures. The total issue size is up to ₹75 Crore via private placement.
Dishman Carbogen Amcis Ltd will hold a board meeting on August 12, 2026, to consider a proposal for raising funds via non-convertible debentures.
Dishman Carbogen Amcis Ltd filed its quarterly shareholding pattern for the quarter ended June 30, 2026. The disclosure includes notes regarding promoter group changes and SBO details.
Dishman Carbogen Amcis repaid Rs. 34.03 Crore toward full principal and interest of NCDs. The redemption was completed on maturity date July 15, 2026.
Dishman Carbogen Amcis paid ₹1.26 Crore in quarterly interest for NCDs. Payment was completed on June 26, 2026.
Subsidiary Carbogen Amcis AG commissioned a 1,200 kWp solar plant in Switzerland. This project supports the company's commitment to sustainability and renewable energy.
Dishman Carbogen Amcis Limited allotted 1,800 Non-Convertible Debentures (NCDs) aggregating to ₹18 Crore. These secured instruments mature on December 9, 2027.
Dishman Carbogen Amcis Limited fixed June 30, 2026, as the record date for NCD interest and redemption payments. Payments for these 4,999 debentures are due on July 15, 2026.
Dishman Carbogen Amcis submitted its Annual Secretarial Compliance Report for FY2026. The report by Ashok P. Pathak & Co. confirms general regulatory compliance with minor procedural observations.
Dishman Carbogen Amcis convened an EGM to approve a ₹2,452 Crore loan from promoter group entity Aamanya AG. The ten-year facility supports increased borrowing limits.
Dishman Carbogen Amcis called an EGM on June 19, 2026, to approve increasing borrowing limits to ₹4,000 Crore. Shareholders will also vote on a ₹1,850 Crore promoter loan.
Dishman Carbogen Amcis scheduled an EGM for June 19, 2026, via video conferencing. Shareholders will vote on increasing borrowing limits and related party transactions.
Dishman Carbogen Amcis reported Q4 FY26 revenue of ₹851cr (up 19% YoY) and EBITDA of ₹163cr. Strategy focuses on high-margin ADC products and India site tech transfers.
Dishman Carbogen Amcis reported strong FY26 performance with revenue up 8.1% and EBITDA margins expanding to 19.3%. Growth is driven by CDMO and Vitamin D analogue segments.
Dishman Carbogen Amcis Ltd reported revenue from operations of ₹851.4 Cr (+18.9% YoY) and net profit of ₹21.7 Cr (-49.7% YoY) for Q4 FY26.
Dishman Carbogen Amcis approved audited results and increased borrowing limits to ₹4,000 Crore. The board also authorized availing ₹2,452 Crore in external commercial borrowings.
Dishman Carbogen Amcis scheduled a board meeting for May 19, 2026. Key agenda items include approving annual results and a ₹1282.50 Crore promoter-group loan.
Dishman Carbogen Amcis' wholly-owned subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., successfully completed an unannounced GMP inspection by China's NMPA on April 14, 2026. The inspection of the Shanghai API facility concluded with no observations. This confirms the site's compliance with international regulatory standards and supports the company's growth in China.